The Food and Drug Administration launched a Rare Disease Framework Initiative on Oct. 14 to change how it reviews drugs and biologics for rare conditions, and it will hold a public meeting on the plan Oct. 28. The agency said in its announcement that only about 5% of rare conditions have an approved treatment.
What the FDA Announced
The agency published a white paper titled “A New Framework for Rare Disease Review” alongside the announcement. The FDA’s Rare Disease Innovation Hub leads the effort, working with the Office of the Commissioner, the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research.
The goal, according to the announcement, is a framework that fits each disease, its patients, the type of product and the evidence a small patient population can realistically produce. Health and Human Services Secretary Robert F. Kennedy Jr. said in the announcement that Americans with rare diseases “cannot afford a regulatory system that treats every condition the same.”
Acting FDA Commissioner Kyle Diamantas said the agency is building a more consistent, predictable and innovative approach to rare disease drug development. Amy Comstock Rick, director of the Rare Disease Innovation Hub, said the framework will improve consistency and predictability for drug sponsors and for patients.
The framework page says the agency may carry out changes through regulations, guidance and internal processes. It gives no implementation timeline and no numerical targets.
The Six Commitments
The announcement lists six things the framework will do. The FDA said it will give clearer and more consistent decisions through tailored guidance and transparent communication. It will bring patients into the process early and at defined milestones. It will use outside experts to customize reviews, build shared training and institutional knowledge and apply risk-based approaches to chemistry, manufacturing and controls review and to inspections before approval. It will also promote new scientific methods and statistical approaches.
The white paper says the agency will keep the legal standards for safety and effectiveness unchanged. Its aim is that “fit-for-purpose evidentiary expectations are the norm” for rare disease reviews, according to the document’s executive summary. The paper describes possible changes to regulations, new or revised guidance on endpoints, trial design and statistics, and more consistent decisions across review divisions. It describes a plan and not finished rules.
The paper lists the programs the agency already runs. They include the Rare Disease Innovation Hub, pilot programs known as RDEA and START, patient listening sessions and a workshop series. A 2024 Government Accountability Office report counted 18 FDA rare disease programs, most launched since 2019, the white paper says, and the count has grown since.
The Numbers Behind the Effort
The white paper puts the number of Americans with a rare disease at about 30 million, or roughly 1 in 10. Under federal law a disease counts as rare if it affects fewer than 200,000 people in the United States. The document counts 7,000 to 10,000 rare conditions worldwide and about 300 million affected people globally.
Applying the agency’s 5% figure to that range of 7,000 to 10,000 conditions gives roughly 350 to 500 conditions with an approved treatment and 6,650 to 9,500 without one. Those totals are a calculation from the white paper’s figures. The paper does not state them.
The white paper also gives a second treatment-gap figure from a separate citation: 95% of rare disease patients lack an approved treatment. That measures patients, while the announcement’s 5% measures conditions, so the two figures count different things.
On cost, the paper says care for a rare disease costs about 10 times more per patient than care for a common one. It cites a 2019 analysis of 379 rare diseases that estimated an annual burden of $997 billion, made up of $449 billion in direct medical costs, $437 billion in indirect costs and $73 billion in non-medical costs. Divided across the 379 diseases, the total averages about $2.6 billion a year per disease, a calculation from the paper’s figures. The paper also links the lack of an approved therapy to a 21.2% annual rise in per-patient costs. About half of recent novel approvals from the two drug centers were for rare diseases, the paper says.
How to Take Part
The agency set a public meeting for Oct. 28 from 1 p.m. to 5 p.m. Eastern. It is a hybrid event at the FDA’s White Oak campus in Silver Spring, Maryland, Building 2, Room 2047, with an online option on Zoom. The Reagan-Udall Foundation for the FDA is facilitating, and registration runs through the foundation’s website.
The meeting page lists four topics for feedback: reviews based on the evidence a disease can realistically produce, consistency and predictability of development and review requirements, how the FDA engages outside parties and chemistry, manufacturing and controls for rare disease therapies. The meeting is open to patients, disease advocates and drug sponsors.
After the meeting, the agency said, feedback will come through sector-specific roundtables, requests for information and internal FDA feedback sessions. The announcement links a request-for-comment form on the HHS website. The meeting page does not list a comment docket number or deadline.
What the Record Does Not Show
The announcement and white paper present the agency’s plan and quote no patient group, drug company or outside expert. They do not say how the new framework will change any application already under review. They name no specific drug that would be reviewed differently. The white paper says the agency expects to report to Congress this fall on a rare disease pilot program and to prepare a separate report covering fiscal 2023 through 2025. It gives no dates for either report.
